Featuring BioEclosion cartridge in biosensing research in breast cancer detection based on exosomes

🌟 Transforming Breast Cancer Diagnosis. BioEclosion’s breakthrough in biosensing technology 🌟

In an exciting development for the field of medical diagnostics, our latest product, the specialized cartridge for biosensing applications, has been featured in a pioneering study published in Biosensors and Bioelectronics. This study, titled “Peptide-based biosensing approaches for targeting breast cancer-derived exosomes”, marks a significant milestone in the non-invasive detection of breast cancer through advanced biosensor technology.

Why This Research Matters
Breast cancer, a leading cause of cancer-related deaths worldwide, requires innovative diagnostic methods for early detection and treatment. The research conducted utilized our cutting-edge cartridge in developing an electrochemical biosensor that precisely targets and quantifies exosomes derived from breast cancer cells. Exosomes, nanovesicles present in all biological fluids, are key biomarkers for cancer due to their molecular composition, reflecting the pathological state of their cells of origin.

Key innovations

  • Use of phage display technology to select peptides with high specificity for exosomes derived from breast cancer cells, demonstrating the effectiveness of peptide-based biosensors as cost-effective and stable alternatives to traditional antibodies.
  • Development of a magneto-actuated immunoassay and electrochemical biosensor integrated with our cartridge technology for the detection and quantification of breast cancer-derived exosomes in serum, showcasing a significant improvement in sensitivity and specificity.
  • Achievement of a lower limit of detection for breast cancer-derived exosomes, highlighting the potential for early diagnosis and monitoring of breast cancer in a non-invasive manner.

Our commitment to innovation
At BioEclosion, we are proud to contribute to such transformative research that has the potential to revolutionize the diagnosis and treatment of breast cancer. Our dedication to providing innovative solutions ensures healthcare professionals can offer more accurate, early detection methods, improving patient outcomes and quality of life.

Looking ahead
The successful application of our cartridge in this study is just the beginning. We are excited to continue our work with researchers and clinicians worldwide, pushing the boundaries of diagnostic technology and making a tangible impact on patient care.

For more details on the study and our biosensing technology, visit Biosensors and Bioelectronics.

#BioEclosion #BreastCancerAwareness #InnovativeDiagnostics #BiosensingTechnology #EarlyDetectionSavesLives

https://doi.org/10.1016/j.bios.2024.116211

.

Discover Bioeclosion Live at the 4YFN MWC Congress in Barcelona

Bioeclosion SL is currently participating in the 4YFN (4 Years From Now) Congress in Barcelona, having been invited by UAB as a spin-off company of the university. 4YFN serves as a parallel event for startups during the Mobile World Congress, the largest event in the mobile industry.

Dr. Jofre Ferrer-Dalmau, CEO of Bioeclosion, along with Dr. Arnau Pallarès, are actively participating in the event and are presenting the Bioeclosion prototype to potential investors and collaborators. This opportunity proves invaluable for showcasing our technology at a specialized event tailored for startups.

BioEclosion Presents Breakthrough Technology and Investment Opportunity at UAB Forum, closure of Arquímedes acceleration program

Last week, Dr. Jofre Ferrer-Dalmau, CEO, presented Bioeclosion at the UAB Investment forum, as closure event of Arquímedes acceleration program. Dr. Ferrer-Dalmau explained Bioeclosion technology, goals and potentiality at a dozen of investors and VC managers. It was highlithed the recently opened Pre-Series A round to complete the development of Bioeclosion MVP.

As a UAB spin-off company, Bioeclosion was invited to join Arquímedes program aiming to help accelerate the company to fulfill its mission and goals. The program combined specialist workshops, personalized mentoring sessions, and an investment forum.

The event was located at Casa de Convalescència, Hospital de Sant Pau, Barcelona, on 13th December 2023.

Bioeclosion SL participates in BioSpain 2023 and Fira de la Innovació de la UAB

Dr. Jofre Ferrer-Dalmau, CEO of BioEclosion, has recently participated in the last edition of BioSpain Congress, organized in Barcelona, 26-28th of September 2023. BioSpain 2023 was a great opportunity to meet with leading companies of biotech sector in Spain, looking forward to find new partners and develop new collaborations.

And last week, Dr. Arnau Pallarès, research scientist in BioEclosion, has participated in the 1st edition of Fira de la Innovació from Universitat Autònoma de Barcelona, in Bellaterra, 17th October 2023. This event has brought together research groups and spinoffs companies that emerged from the UAB. It was a great opportunity to meet new collaborators and companies around the UAB.
Beasides, Bioeclosion has also attended the inaugural session of the Arquímedes startup acceleration program, organized by the UAB Research Park.

First meeting of the EChiLiBRiST consortium

All partners of EChiLiBRiST consortium met February 8-10 in Barcelona for the kick-off meeting of the project. The consortium, led by ISGlobal – Institut de Salut Global de Barcelona, is formed by 13 research institutions from Europe, Africa and North America. The main goal of the project is to develop and clinically validate a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and thus, enhance child survival.

BioEclosion S.L. has a key role in the consortium, as presented by CEO Dr. Jofre Ferrer-Dalmau in the meeting. The development and validation of BioEclosion’s MagnetPlex point-of-care platform (based on the disposable cartridge patented by BioEclosion) is central for the project. The MagnetPlex platform will be used to obtain quantitative and fast measurements of two biomarkers that can predict the severity of febrile patients, enabling the clinicians to take almost immediate clinical decisions.

The test will be developed and produced by BioEclosion, UAB – Universitat Autònoma de Barcelona – Biosensing and Bioanalysis Group, and Eurecat.

For more information, please check the project website.

Kick-off meeting of AmpliSens project, led by BioEclosion

The AmpliSens Consortium met for the kick-off of the project past 15th of December 2022. The Consortium is led by BioEclosion, partnering with ‘Universitat Autònoma de Barcelona’ (Research group led by Prof. Isabel Pividori), ISGlobal (Research group led by Prof. Quique Bassat) and EureCat technology center. Dr. Jofre Ferrer-Dalmau, CEO from BioEclosion S.L., will coordinate this project, granted under the call for ‘Proyectos de colaboración público-privada 2021’ from Spanish Ministry of Science and Innovation, and funded from European Union – Next Generation EU/PRTR (Sept 2022 – Aug 2025).

The aim of the project is to develop a rapid and portable molecular test for the screen-out of neonatal sepsis due to Group B streptococcus (GBS) of the suspected newborn and for the screening of pregnant women. The proposed test can be used both in low resource settings where microbiological cultures are not available, and in high income countries to dramatically improve turnaround times for results and reduce costs.

For more information, check the project website.